Related Experiment Videos
Viral and non-viral vectors for cancer gene therapy
1Department of Thoracic and Cardiovascular Surgery, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Background:
Our research has focused on developing improved delivery vectors for treating cancer by gene therapy using the tumor suppressor p53 gene.
Materials And Methods:
Recombinant viral and non-viral vectors were used to deliver the p53 gene into non-small cell lung cancer (NSCLC) cells either in culture or as a subcutaneous tumor. Transduction of tumor cells was measured by beta-gal expression while tumor cell proliferation was used to measure the effect of p53.
Results:
High level transduction was obtained in vitro and in vivo with a recombinant adenoviral vector, resulting in tumor cell growth inhibition in both models. A targeted, non-viral gene delivery vector based on the use of an EGF/DNA polyplex also resulted in efficient (as high as 66% transduction) and specific gene delivery in vitro when replication defective adenovirus was used as an endosome release agent.
Conclusion:
These vectors now provide improved methods to deliver therapeutic genes for cancer treatment by gene therapy.
Insights
Researchers developed novel gene therapy vectors for cancer treatment. These vectors efficiently deliver the p53 gene to non-small cell lung cancer cells, inhibiting tumor growth.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Focus on developing improved delivery vectors for cancer gene therapy.
- Utilizing the tumor suppressor p53 gene for therapeutic applications.
Purpose of the Study:
- To evaluate recombinant viral and non-viral vectors for p53 gene delivery.
- To assess the efficacy of p53 gene therapy in non-small cell lung cancer (NSCLC) models.
Main Methods:
- Delivery of the p53 gene into NSCLC cells in vitro and in vivo using viral and non-viral vectors.
- Measurement of gene transduction via beta-gal expression.
- Assessment of tumor cell proliferation to determine p53 gene effect.
Main Results:
- High-level transduction achieved with a recombinant adenoviral vector in vitro and in vivo.
- Significant tumor cell growth inhibition observed in both models.
- Efficient and specific gene delivery (up to 66% transduction) using an EGF/DNA polyplex non-viral vector in vitro, enhanced by adenovirus.
Conclusions:
- Developed improved vectors for therapeutic gene delivery in cancer gene therapy.
- Demonstrated the potential of these vectors for effective p53 gene delivery and tumor suppression.